...
首页> 外文期刊>Vaccine >Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses
【24h】

Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses

机译:接种2或3剂疫苗的婴儿对7价肺炎球菌结合疫苗加强剂量抗体应答的可比性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-conjugated pneumococcal vaccine (PCV-7) at 2,4 and 11 months and at 2, 3, 4 and 11 months of age,as measured by double adsorption ELISA. Pre- and post-booster levels following the 2 + 1 - and 3 + 1-dose schedule were comparable for 5 out of 7 serotypes except for serotypes 6B and 19F. The proportion of children reaching post-booster antibody thresholds were comparable except for 6B (>= 1.0 mu g/ml and >= 5.0 mu g/ml) and 19F (>= 5.0 mu g/ml). Surveillance studies are warranted for vaccine impact on 6B and 19F disease cases after reduced-dose PCV-7 schedules
机译:在这项队列研究中,我们比较了分别在2,4和11个月以及2、3、4和11个月接受7价CRM197结合的肺炎球菌疫苗(PCV-7)免疫的婴儿之间的IgG抗体水平,吸附ELISA。除6B和19F血清型外,遵循2 +1和3 +1剂量方案的加强前后的水平与7种血清型中的5种相当。除6B(> = 1.0μg / ml和> = 5.0μg / ml)和19F(> = 5.0μg / ml)外,达到加强后抗体阈值的儿童比例相当。在减少剂量的PCV-7时间表后,有必要对疫苗对6B和19F疾病的影响进行监视研究

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号